Buy Mexidol pills 0.125 g, 30 pcs
  • Buy Mexidol pills 0.125 g, 30 pcs

Mexidol® [Emoxypine succinate]

Homefarm Ltd.
1398 Items
Dosage form
Brand & Manufacturer
Package Size
  • done All payments are SSL encrypted
  • done Full Refund if you haven't received your order
  • done International shipping to the USA, UK and Europe

Clinical Pharmacology

Metromicon-Neo is a combined preparation with antiprotozoal, antifungal and antibacterial action.


Vaginal infections:

  • vaginal candidiasis;
  • Trichomonas vaginitis and vulvovaginitis, bacterial vaginosis;
  • mixed vaginal infection.


1 suppository contains:

Active substances: miconazole nitrate - 100 mg, metronidazole - 500 mg.

Excipients: semisynthetic glycerides.

Mexidol is marketed under different brands and generic names, and comes in different dosage forms:

Brand nameManufacturerCountryDosage form
Astrox Homefarm Ltd Russia solution
MexiB6 mexidol-pyridoxine) pills
Mexiprim Nizhpharm Russia solution
Mexicor EcoFarmInvest Russia solution
Mexidol Farmasoft Russia ampoules
Mexiprim Nizhpharm Russia ampoules
Cerecard EcoPharmPlus Russia solution
Mexiprim Nizhpharm Russia pills
Neurox Sotex Russia ampoules
Mexifin Pharmaceutical NPC Russia ampoules
Mexicor EcoFarmInvest Russia ampoules
Mexidol Farmasoft Russia pills

No customer reviews for the moment.

Write your review

Write your review

Mexidol® [Emoxypine succinate]

Dosage and Administration


Acute vaginitis, bacterial vaginosis: on 1 suppository in the morning and for the night within 7 days in a row.

Chronic vaginitis: 1 suppository 1 time per day, immediately before bedtime, for 14 consecutive days.

Often recurrent vaginitis or in the absence of positive clinical dynamics in the treatment of other methods: 1 suppository in the morning and at night for 14 days.

Before freeing the suppository from the contour packaging using scissors (cut the film along the suppository contour), insert it deeply into the vagina.

Adverse reactions

Local reactions: burning, itching, irritation of the mucous membrane of the vagina and increased swelling. Due to inflammation of the vaginal mucosa with vaginitis, irritation may increase after the introduction of the first suppository or by the third day of treatment. These complications quickly disappear after stopping treatment.

From the gastrointestinal tract: pain or cramps in the abdomen, "metallic" taste, dry mouth, constipation, diarrhea, loss of appetite, nausea, vomiting.

From the nervous system: headache, motor disorders (ataxia), dizziness, psycho-emotional disorders, convulsions.

From the hemopoietic system: leukopenia.

Allergic reactions: skin rashes, including urticaria.

Carefully: with hepatic and renal failure, porphyria, impaired blood formation and diseases of the peripheral and central nervous system, diabetes, microcirculation disorders, during pregnancy (II and III trimesters).

Drug interactions

In connection with the ingress of metronidazole into the systemic circulation, the following interaction reactions may be noted with simultaneous use with certain substances:

Oral anticoagulants: effect of indirect anticoagulants increases.

Disulfiram: there may be violations of the central nervous system (mental reactions); no, metronidazole should be prescribed to patients who have taken disulfiram in the last 2 weeks.

Phenytoin: the concentration of phenytoin in the blood increases, and the concentration of metronidazole in the blood decreases.

Lithium preparations: there may be an increase in their toxicity.

Phenobarbital: decreases the concentration of metronidazole in the blood.

Cimetidine: may increase the concentration of metronidazole in the blood.

Astemizol and terfenadine: metronidazole and miconazole inhibit the metabolism of these drugs and increase plasma concentration.

Ethanol: The interaction of metronidazole with ethanol causes disulfiram-like reactions.

Pregnancy and Lactation

The purpose of the drug is contraindicated in the first trimester of pregnancy. Application in the II and III trimesters of pregnancy is possible only if the potential benefit to the mother outweighs the possible risk to the fetus.

If necessary, the appointment of the drug during lactation breastfeeding should be discontinued, as metronidazole penetrates into breast milk. Breastfeeding can be resumed 24-48 hours after the end of treatment.

Special instructions

When using the drug should refrain from sexual contact. In order to avoid re-infection, simultaneous treatment of the sexual partner is necessary. In the case of Trichomonas vaginitis, it is advisable to simultaneously treat the sexual partner with metnnidazole for oral administration.

During treatment and at least for 24-48 hours after the end of the course of treatment, ethanol administration should be avoided (ethanol intolerance is possible).

The simultaneous use of the drug with contraceptive diaphragms and rubber or latex condoms is not recommended (interaction with price suppositories is possible).

With strong irritation of the vagina, drug treatment should be discontinued.

Suppositories should be used only intravaginally, they can not be swallowed or used in another way.

In the case of the use of the drug in conjunction with metronidazole for oral administration, especially with repeated courses, control of the pattern of peripheral blood is necessary (danger of leukopenia).

Influence on ability to drive motor transport and management of potentially dangerous mechanisms: It is recommended to be careful, as the possible negative impact on the ability to drive a car and control complex machinery cannot be excluded. If side effects arise from the central nervous system, one should refrain from driving and working with potentially dangerous machinery.


At observance of the recommended doses, due to the low absorption of the drug, no overdose cases have been identified.

Possible symptoms: nausea, vomiting, abdominal pain, diarrhea, itching, metallic taste in the mouth, ataxia, dizziness, paresthesia, peripheral neuropathy (with prolonged use in high doses), convulsions, leukopenia, dark urine staining (due to overdose of metronidazole) .

Symptoms of miconazole overdose have not been identified.

Treatment: symptomatic and supportive therapy, with occasional ingestion - gastric lavage.

  • Brand name: Metromicon-Neo
  • Active ingredient: Metronidazole, Miconazole
  • Dosage form: Vaginal suppositories
  • Manufacturer: Anzhero-Sudzhensky HFZ
  • Country of Origin: Russia

Studies and clinical trials of Mexidol (Click to expand)

  1. Bioenergetic mechanisms of the antihypoxic effect of mexidol, a succinate-containing derivative of 3-hydroxypyridine
  2. Effect of mexidol on the content of transmitter monoamines and amino acids in rat brain structures
  3. Antioxidant and hypolipidemic properties of mexidol and emoxypine during prolonged immobilization stress
  4. Antihypoxic and Antinecrotic Effect of Mexidol in Skin Ischemia
  5. Lymphotropic Effect of Mexidol in Reactive Fever
  6. Effect of mexidol and nitroglycerine on iron-sulfur centers, cytochrome P-450, and nitric oxide formation in liver tissue of experimental animals
  7. Lymphotropic effect of dimephosphon, mexidol, and ketorolac is realized via activation of the lymphangion and stimulation of lymph formation
  8. Histo- and Cytoarchitectonics of the Hippocampus in Young Rats Injected with Propofol and Mexidol
  9. Evaluation of Effects of Histochrome and Mexidol on Structural and Functional Characteristics of the Brain in Senescence-Accelerated OXYS Rats by Magnetic Resonance Imaging
  10. The effects of Mexidol on the acquisition of food-related conditioned reflexes and synaptic ultrastructure in field Ca1 of the rat hippocampus after single acoustic stimuli with ultrasonic components
  11. Antioxidants L-tocopherol, emoxypine, and mexidol modify the effect of antidepressants in mice
  12. Voltammetric Determination of Mexidol
  13. Synergism of sulfur-containing phenol (SO-4) with mexidol, α-tocopherol, and phospholipids
  14. The Action of Mexidol on the State of Conditioned Reflex Activity after Traumatic Brain Lesions
  15. Postresuscitation Recovery of Functional Activity of Central Nervous System in Rats during Combination Treatment with Mexidol and Neuropeptides Delta Sleep-Inducing Peptide and Oxytocin
  16. Identification and quantitative determination of specific impurity in mexidol and emoxypine by high-performance liquid chromatography
  17. Features of the antihypoxic action of mexidol associated with its specific effect on energy metabolism
  18. P.3.001 Discriminative stimulus effects of mexidol in rats
  19. P.3.022 Antistressory effect of mexidol in inbredC57BL/6 and BALB/C mice
  20. P.5.007 Perspectives of the use of a new antioxidant mexidol in the treatment of Parkinson's disease
  21. P.5.016 Stress-protective effect of mexidol on different levels of natural altitudes
  22. P.5.042 Enhancement of the activity of antiepileptic drugs in combination with mexidol
  23. P.5.084 Pharmacokinetics and biotransformation of mexidol in C57BL/6 and BALB/C inbred mice
  24. P.1.015 Cerebrovascular effects of mexidol in conditions of separate and combined vascular pathology of brain and heart

Customers who bought this product also bought:

8 other products in the same category: